Physician profile
Heyer Cp Devarapalli
NPI 1588704381
$30,510.23
in general payments reported to CMS, 2019-2025
58 companies · $4,244 in 2025
The $4,244 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,535 · 2020: $1,732 · 2021: $4,965 · 2022: $4,985 · 2023: $3,705 · 2024: $6,344 · 2025: $4,244.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,292.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $3,421.54 | 2019-2025 | Jardiance, Synjardy |
| Amgen INC. | $3,121.28 | 2021-2025 | Evenity, Repatha, Repatha |
| Lilly USA, LLC | $1,869.44 | 2019-2025 | Mounjaro, Jardiance, Trulicity |
| Novo Nordisk INC | $1,833.40 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,791.35 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Janssen Pharmaceuticals, INC | $1,658.98 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $1,606.64 | 2019-2024 | Eliquis, Camzyos |
| Smith+Nephew, INC. | $1,474.36 | 2019-2025 | Grafix Pl, Stravix Pl, Oasis |
| Glaxosmithkline, LLC. | $1,380.83 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Organogenesis INC. | $1,300.71 | 2019-2024 | Puraply, Affinity, Puraply Wound Matrix |
| Abbott Laboratories | $1,098.00 | 2020-2025 | Freestyle Libre 3, Proclaim, Eterna |
| Sanofi-Aventis U.S. LLC | $1,024.54 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $901.45 | 2021-2025 | |
| Abbvie INC. | $884.02 | 2021-2025 | Vraylar |
| Pfizer INC. | $839.67 | 2019-2025 |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heyer Devarapalli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.